Miller Fisher syndrome (MFS) is a variant of Guillain-Barre syndrome (GBS) characterized by the clinical triad of ophthalmoplegia (paralysis of extraocular muscles), ataxia (cerebellar-like gait instability), and areflexia. The pathophysiology involves molecular mimicry: antibodies generated against ganglioside epitopes on the surface of the triggering pathogen (commonly Campylobacter jejuni or Haemophilus influenzae) cross-react with GQ1b gangliosides that are highly concentrated in cranial nerves III, IV, and VI (controlling eye movements), cerebellar neurons, and peripheral nerve nodes of Ranvier. Anti-GQ1b antibodies are present in more than 90% of MFS cases and are a key diagnostic marker. Unlike classic GBS, MFS typically does not progress to respiratory failure, but overlap syndromes with ascending weakness can occur. The nurse performs serial neurological assessments including extraocular movements, limb strength, deep tendon reflexes, and respiratory function (forced vital capacity, negative inspiratory force), monitors for progression to classic GBS pattern, administers IVIG as prescribed, implements fall precautions for ataxia, and provides supportive care including DVT prophylaxis and pain management.